top of page
Previous talks given in 2024
Prof. Stefaan van Gool (Head of Translational Oncology, IOZK)
Thursday, January 25, 2024
Multiphase combined treatment for GBM: update and expansion of patient data
We recently published the clinical evolution and survival data of 50 adults with GBM treated with individualized multimodal immunotherapy (IMI) as part of a multiphase combined treatment. We now expanded the patient group, and the period of follow-up (till November 2023) using the same patient definition.
Multiphase combined treatment for GBM: update and expansion of patient data
We recently published the clinical evolution and survival data of 50 adults with GBM treated with individualized multimodal immunotherapy (IMI) as part of a multiphase combined treatment. We now expanded the patient group, and the period of follow-up (till November 2023) using the same patient definition.
Mr. Ranjeev Bhangoo (Consultant Neurosurgeon, Kings College Hospital)
Thursday, February 22, 2024
Maximising tumour resection whilst preserving Quality of Life - the neurosurgeon's role and armamentarium in achieving an Oncofunctional balance
Mr Ranjeev Bhangoo is a Consultant Neurosurgeon and Clinical Director of Neuroscience at King's College Hospital London and The London Clinic. His subspeciality interest is neuro-oncology and he spent a year post training at the Institute Gustauve Rossy in Paris learning and developing new techniques for the treatment of Brain tumours. He is also the neurosurgeon to the European School of Oncology and the European Society of Therapeutic Radiation Oncology.
His talk will cover the use of techniques such as Brain Path minimally invasive neurosurgery, Navigated Transcranial Magnetic Stimulation and Laser Interstitial Thermal Therapy (LITT) to maximise tumour resection and consider surgery for the previously unresectable.
Maximising tumour resection whilst preserving Quality of Life - the neurosurgeon's role and armamentarium in achieving an Oncofunctional balance
Mr Ranjeev Bhangoo is a Consultant Neurosurgeon and Clinical Director of Neuroscience at King's College Hospital London and The London Clinic. His subspeciality interest is neuro-oncology and he spent a year post training at the Institute Gustauve Rossy in Paris learning and developing new techniques for the treatment of Brain tumours. He is also the neurosurgeon to the European School of Oncology and the European Society of Therapeutic Radiation Oncology.
His talk will cover the use of techniques such as Brain Path minimally invasive neurosurgery, Navigated Transcranial Magnetic Stimulation and Laser Interstitial Thermal Therapy (LITT) to maximise tumour resection and consider surgery for the previously unresectable.
Dr. Cressida Lorimer (Clinical Oncologist, Brighton)
Tuesday, March 19, 2024
The management of older and frailer patients with GBM – are we offering the right treatment to the right patient?
We recently completed the multicentre BRITER study, a prospective imaging study looking at using baseline MRI scans to predict changes in quality of life for older patients undergoing radiotherapy for newly diagnosed GBM. I will cover an overview of the evidence behind the treatment strategies for older and frailer patients with GBM, the increase in interest in the use of geriatric assessment techniques in this cohort and the results of the BRITER study.
The management of older and frailer patients with GBM – are we offering the right treatment to the right patient?
We recently completed the multicentre BRITER study, a prospective imaging study looking at using baseline MRI scans to predict changes in quality of life for older patients undergoing radiotherapy for newly diagnosed GBM. I will cover an overview of the evidence behind the treatment strategies for older and frailer patients with GBM, the increase in interest in the use of geriatric assessment techniques in this cohort and the results of the BRITER study.
Dr. Raj Jena (Group Leader, University of Cambridge)
Thursday, April 25, 2024
I am faking it - have I got your attention?
I have always found it fascinating that the brain, such a delicate structure, can tolerate such high doses of radiation with relatively little obvious adverse effects. However, digging under the surface, we know that our patients with brain tumours suffer a number of subtle neurocognitive deficits, from short term memory registration, and fatigue to task switching and holding attention. We are undertaking initial work to use synthetic MRI to build maps of white matter connectivity, and auto-segmentation algorithms to parse out the key processing areas of the brain - the so called 'attention networks'. We believe that this approach will give us a better ability to correlate radiation dose and neurocognitive outcomes for our patients.
I am faking it - have I got your attention?
I have always found it fascinating that the brain, such a delicate structure, can tolerate such high doses of radiation with relatively little obvious adverse effects. However, digging under the surface, we know that our patients with brain tumours suffer a number of subtle neurocognitive deficits, from short term memory registration, and fatigue to task switching and holding attention. We are undertaking initial work to use synthetic MRI to build maps of white matter connectivity, and auto-segmentation algorithms to parse out the key processing areas of the brain - the so called 'attention networks'. We believe that this approach will give us a better ability to correlate radiation dose and neurocognitive outcomes for our patients.
Prof. Michael Jenkinson (Liverpool)
Tuesday, June 18, 2024
Meningioma: The good, the bad and the ugly
Although considered benign and eminently treatable with surgery, meningioma has been a Cinderella subject for decades. The increasing use of brain imaging has led to a growth in the number of incidental meningioma diagnosis and anxious patients. How can we best manage these patients and avoid the harm from unnecessary treatment. For those with symptomatic meningioma undergoing surgery, who will benefit from post-operative radiotherapy and how can we reduce the risk of seizures? Finally, where next for that small group of patients that will have multiple episodes of recurrence and treatment - will we find new systematic treatments?
Meningioma: The good, the bad and the ugly
Although considered benign and eminently treatable with surgery, meningioma has been a Cinderella subject for decades. The increasing use of brain imaging has led to a growth in the number of incidental meningioma diagnosis and anxious patients. How can we best manage these patients and avoid the harm from unnecessary treatment. For those with symptomatic meningioma undergoing surgery, who will benefit from post-operative radiotherapy and how can we reduce the risk of seizures? Finally, where next for that small group of patients that will have multiple episodes of recurrence and treatment - will we find new systematic treatments?
bottom of page